Quantitative BCR/ABL1 PAnel WIth ABL1 Mutation Detection

BCR/ABL1 Panel Information

Precipio’s quantitative BCR/ABL1 Panel detects three major BCR/ABL1 isoforms (p190, p210, and p230) and one minor isoform (p203) associated with BCR/ABL1-induced leukemogenesis, including chronic myeloid leukemia (CML) and acute lymphocytic leukemia (ALL). This panel has been validated as a lab derived test at Precipio. It has not been approved by the FDA.

Product Brochure Co-Expression Case

Development Of Precipio’s Quantitative BCR/ABL1 Panel

Precipio’s own clinical hematopathology laboratory developed the quantitative BCR/ABL1 panel to address the issues of turn-around time and accurate, comprehensive molecular testing for breakpoints associated with the BCR/ABL1 oncogene. Precipio’s clinical hematopathology lab takes a panel approach to gene mutation detection and monitoring of BCR/ABL1 breakpoints to identify incidence of single mutations, mutation changes, and co-expression in a single assay run on one platform for all four breakpoints. This provides our lab with a more efficient testing workflow and enables rapid turn around time. In addition to breakpoint detection and monitoring, the assay also detects ABL1 gene mutation clusters associated with specific therapeutic indications, enabling the lab to eliminate the need for reflex sequencing of the ABL1 gene, where otherwise necessary.

BCR/ABL1 Panel Configurations

The BCR/ABL1 panel comes pre-plated or as reagent sets with optimized primers and embedded mutant, NTC, and wild type controls for p.190, p.203, p.210, and p.230 breakpoints. This simplifies lab inventory management by providing a complete molecular assay without tracking multiple SKUs of single gene testing assays that require separate control kits.

12-sample pre-plated, and vialed free flow configurations are available for the quantitative BCR/ABL1 panel. Custom configurations are also possible.

Assay Workflow

Sample preparation is based on standard RNA isolation and cDNA preparation techniques. Most HRM-enabled RT-PCR instruments can run the BCR/ABL1 assay after cDNA samples are plated. Data is captured in real time and can be uploaded for automated analysis to determine the presence of p.190, p.203, p.210, p.230 breakpoints as well as ABL1 gene mutations.